Target Name: SLC22A15
NCBI ID: G55356
Other Name(s): solute carrier family 22 (organic cation transporter), member 15 | Solute carrier family 22 member 15 | Fly-like putative organic ion transporter 1 | Flipt 1 | trans-like protein | Fly-like putative transporter 1 | OTTHUMP00000013798 | fly-like putative transporter 1 | PRO34686 | fly-like putative organic ion transporter 1 | FLIPT1 | Solute carrier family 22 (organic cation transporter), member 15 | solute carrier family 22 member 15 | Trans-like protein | flipt 1 | DKFZp761G0313 | S22AF_HUMAN

SLC22A15: A Potential Drug Target and Biomarker

SLC22A15 is a member of the SLC22 family, which is known as the solute carrier family 22. This family is responsible for the transport of a variety of molecules, including organic cations, across cell membranes. SLC22A15 is a cation transporter, which means it transports positively charged ions, such as sodium ions, across cell membranes.

SLC22A15 has been identified as a potential drug target due to its involvement in the regulation of ion homeostasis in the body. Disruptions in SLC22A15 function have been linked to a variety of diseases, including hypertension, heart failure, and neurodegenerative disorders. Additionally, SLC22A15 has also been shown to be involved in the regulation of pain perception and neurotransmitter release, which could make it a useful target for the treatment of pain conditions.

SLC22A15 has also been identified as a potential biomarker for a variety of diseases. For example, levels of SLC22A15 have been shown to be elevated in the blood of individuals with hypertension, which could be used as a diagnostic marker for this condition. Additionally, SLC22A15 levels have also been shown to be elevated in the blood of individuals with heart failure, which could be used as a diagnostic marker for this condition.

SLC22A15 is also a potential target for drug development due to its involvement in the regulation of ion homeostasis. Drugs that target SLC22A15 have the potential to treat a variety of conditions, including hypertension, heart failure, and neurodegenerative disorders. Additionally, SLC22A15 has also been shown to be involved in the regulation of pain perception and neurotransmitter release, which could make it a useful target for the treatment of pain conditions.

In conclusion, SLC22A15 is a promising drug target due to its involvement in the regulation of ion homeostasis and its potential as a biomarker for a variety of diseases. Further research is needed to fully understand the role of SLC22A15 in the regulation of ion homeostasis and its potential as a drug target and biomarker.

Protein Name: Solute Carrier Family 22 Member 15

Functions: Probably transports organic cations (By similarity). Appears not to be the agmatine transporter

More Common Targets

SLC22A16 | SLC22A17 | SLC22A18 | SLC22A18AS | SLC22A2 | SLC22A20P | SLC22A23 | SLC22A24 | SLC22A25 | SLC22A3 | SLC22A31 | SLC22A4 | SLC22A5 | SLC22A6 | SLC22A7 | SLC22A8 | SLC22A9 | SLC23A1 | SLC23A2 | SLC23A3 | SLC24A1 | SLC24A2 | SLC24A3 | SLC24A3-AS1 | SLC24A4 | SLC24A5 | SLC25A1 | SLC25A10 | SLC25A11 | SLC25A12 | SLC25A13 | SLC25A14 | SLC25A15 | SLC25A16 | SLC25A17 | SLC25A18 | SLC25A19 | SLC25A2 | SLC25A20 | SLC25A21 | SLC25A21-AS1 | SLC25A22 | SLC25A23 | SLC25A24 | SLC25A24P1 | SLC25A25 | SLC25A25-AS1 | SLC25A26 | SLC25A27 | SLC25A28 | SLC25A29 | SLC25A3 | SLC25A30 | SLC25A31 | SLC25A32 | SLC25A33 | SLC25A34 | SLC25A35 | SLC25A36 | SLC25A37 | SLC25A38 | SLC25A38P1 | SLC25A39 | SLC25A3P1 | SLC25A4 | SLC25A40 | SLC25A41 | SLC25A42 | SLC25A43 | SLC25A44 | SLC25A45 | SLC25A46 | SLC25A47 | SLC25A47P1 | SLC25A48 | SLC25A48-AS1 | SLC25A5 | SLC25A5-AS1 | SLC25A51 | SLC25A51P1 | SLC25A52 | SLC25A53 | SLC25A5P1 | SLC25A6 | SLC26A1 | SLC26A10P | SLC26A11 | SLC26A2 | SLC26A3 | SLC26A4 | SLC26A4-AS1 | SLC26A5 | SLC26A5-AS1 | SLC26A6 | SLC26A7 | SLC26A8 | SLC26A9 | SLC26A9-AS1 | SLC27A1 | SLC27A2